Orforglipron
The first weight loss drug in the GLP-1 class that comes as a daily pill rather than a weekly injection — and unlike Rybelsus, you can take it with food and water. Made by Eli Lilly, it is technically a small molecule rather than a peptide, but it activates the same GLP-1 receptor as semaglutide and tirzepatide. Phase 3 trials in 2026 (ACHIEVE-1 in diabetes, ATTAIN-1 and ATTAIN-2 in obesity) have shown around 14-15% body weight loss. Likely to be the first oral GLP-1 to compete on weight loss with the injectables.
Dosage
Fixed dose: 3 mg starting → up to 36 mg oral once daily (titrated)
Dosages shown are for research reference only. Always consult a qualified healthcare provider.
Administration
Oral (tablet, once daily, no food or water restrictions)
Shop Research-Grade Peptides
99%+ purity · US-based · third-party lab tested
Getting Started — Here's What You'll Need
Effects
Weight Loss
Approximately 14.7% mean body weight loss at 36 weeks in Phase 2 obesity trials.
Oral Bioavailability
First true oral GLP-1 with no food or water restrictions — major practical advantage over Rybelsus.
Glycemic Control
Phase 3 ACHIEVE-1 trial in type 2 diabetes showing significant HbA1c reductions.
Once-Daily Dosing
29-49 hour half-life supports stable once-daily oral dosing without injection burden.
Mechanism of Action
Orforglipron is a non-peptide small molecule that activates the GLP-1 receptor through binding outside the orthosteric peptide-binding pocket — a true biased GLP-1 receptor agonist rather than a structural mimic of native GLP-1. Because it is a small molecule rather than a peptide, it is not destroyed by gastric acid or proteolytic enzymes in the gut, which is why it can be taken orally without the strict fasting and water-restriction requirements that limit semaglutide's oral formulation (Rybelsus).
Receptor activation triggers the same downstream signalling cascades as injectable GLP-1 agonists: stimulation of glucose-dependent insulin secretion from pancreatic beta cells, suppression of glucagon release from alpha cells, slowing of gastric emptying, and central appetite suppression through hypothalamic and brainstem GLP-1 receptors. Importantly, orforglipron's biased agonism profile favours G-protein signalling over beta-arrestin recruitment, which preclinical data suggests may reduce receptor desensitisation over chronic dosing.
The pharmacokinetic profile gives it a half-life of roughly 29-49 hours, comfortably supporting once-daily oral dosing with stable plasma concentrations. In Phase 2 obesity trials, orforglipron produced approximately 14.7% mean body weight reduction at 36 weeks at the highest dose tested. Phase 3 results in 2026 (ACHIEVE-1 for type 2 diabetes, ATTAIN-1 and ATTAIN-2 for obesity) have positioned it as the leading candidate to be the first true oral GLP-1 with weight-loss efficacy approaching that of weekly injectables, removing one of the main barriers to GLP-1 therapy adoption.
Regulatory Status
Not yet FDA approved. Phase 3 trials reading out through 2026; FDA filing for type 2 diabetes and obesity expected late 2026 (Eli Lilly).
Risks & Safety
Common
nausea, vomiting, diarrhea, constipation, dyspepsia. Side-effect frequency in Phase 3 has been comparable to injectable GLP-1 agonists.
Serious
pancreatitis, gallstones, dehydration.
Rare
thyroid C-cell tumour signal as a class warning, severe allergic reactions. Long-term safety still being characterised.
Compare Orforglipron With
Research Papers
5Published: May 6, 2026
AI Summary
The 2025 CVOT Summit summary highlights orforglipron's ATTAIN-1 results among other recent cardio-kidney-metabolic trials. It places oral orforglipron alongside other emerging therapies likely to influence guidelines.
Published: April 17, 2026
AI Summary
A bridging study showing that the orforglipron tablet and capsule formulations produce equivalent drug exposure with similar tolerability. This supports use of the tablet form going into wider clinical use.
Published: April 16, 2026
AI Summary
A network meta-analysis of 19 trials ranking GLP-1 mono-agonists. Orforglipron 36 mg sat behind high-dose semaglutide but ahead of standard-dose semaglutide on a combined cardiometabolic score, with placebo-adjusted weight loss above 10%.
Published: December 20, 2025
AI Summary
The phase 3 ATTAIN-2 trial in 1,613 adults with obesity and type 2 diabetes showed average weight loss of 5-10% over 72 weeks depending on dose, versus 2.5% with placebo, plus improved HbA1c. Side effects were mainly gastrointestinal and one death in the orforglipron group could not be ruled out as treatment-related.
Published: September 7, 2023
AI Summary
The phase 2 trial in 272 adults with obesity and no diabetes showed average weight loss of roughly 9-15% over 36 weeks, much more than the 2% on placebo. Up to 17% of participants stopped treatment due to gastrointestinal side effects.
Frequently Asked Questions
What is Orforglipron?
The first weight loss drug in the GLP-1 class that comes as a daily pill rather than a weekly injection — and unlike Rybelsus, you can take it with food and water. Made by Eli Lilly, it is technically a small molecule rather than a peptide, but it activates the same GLP-1 receptor as semaglutide and tirzepatide. Phase 3 trials in 2026 (ACHIEVE-1 in diabetes, ATTAIN-1 and ATTAIN-2 in obesity) have shown around 14-15% body weight loss. Likely to be the first oral GLP-1 to compete on weight loss with the injectables.
What is Orforglipron used for?
The first weight loss drug in the GLP-1 class that comes as a daily pill rather than a weekly injection — and unlike Rybelsus, you can take it with food and water. Made by Eli Lilly, it is technically a small molecule rather than a peptide, but it activates the same GLP-1 receptor as semaglutide and tirzepatide. Phase 3 trials in 2026 (ACHIEVE-1 in diabetes, ATTAIN-1 and ATTAIN-2 in obesity) have shown around 14-15% body weight loss. Likely to be the first oral GLP-1 to compete on weight loss with the injectables.
What is the dosage for Orforglipron?
Phase 3 trials: 3 mg oral once daily as the starting dose, escalated every 4 weeks to maintenance doses of 12, 24, or 36 mg once daily. Can be taken at any time of day, with or without food and water — a significant practical advantage over Rybelsus.
What are the side effects of Orforglipron?
Common: nausea, vomiting, diarrhea, constipation, dyspepsia. Side-effect frequency in Phase 3 has been comparable to injectable GLP-1 agonists. Serious: pancreatitis, gallstones, dehydration. Rare: thyroid C-cell tumour signal as a class warning, severe allergic reactions. Long-term safety still being characterised.
How does Orforglipron work?
Orforglipron is a non-peptide small molecule that activates the GLP-1 receptor through binding outside the orthosteric peptide-binding pocket — a true biased GLP-1 receptor agonist rather than a structural mimic of native GLP-1. Because it is a small molecule rather than a peptide, it is not destroyed by gastric acid or proteolytic enzymes in the gut, which is why it can be taken orally without the strict fasting and water-restriction requirements that limit semaglutide's oral formulation (Rybelsus). Receptor activation triggers the same downstream signalling cascades as injectable GLP-1 agonists: stimulation of glucose-dependent insulin secretion from pancreatic beta cells, suppression of glucagon release from alpha cells, slowing of gastric emptying, and central appetite suppression through hypothalamic and brainstem GLP-1 receptors. Importantly, orforglipron's biased agonism profile favours G-protein signalling over beta-arrestin recruitment, which preclinical data suggests may reduce receptor desensitisation over chronic dosing. The pharmacokinetic profile gives it a half-life of roughly 29-49 hours, comfortably supporting once-daily oral dosing with stable plasma concentrations. In Phase 2 obesity trials, orforglipron produced approximately 14.7% mean body weight reduction at 36 weeks at the highest dose tested. Phase 3 results in 2026 (ACHIEVE-1 for type 2 diabetes, ATTAIN-1 and ATTAIN-2 for obesity) have positioned it as the leading candidate to be the first true oral GLP-1 with weight-loss efficacy approaching that of weekly injectables, removing one of the main barriers to GLP-1 therapy adoption.
How is Orforglipron administered?
Orforglipron is administered via oral (tablet, once daily, no food or water restrictions).
What is the half-life of Orforglipron?
The half-life of Orforglipron is Approximately 29-49 hours, supporting once-daily oral dosing.
Is Orforglipron legal?
Not yet FDA approved. Phase 3 trials reading out through 2026; FDA filing for type 2 diabetes and obesity expected late 2026 (Eli Lilly).
Sources. This profile is built from peer-reviewed papers indexed on PubMed, FDA-approved labelling where available, and published clinical guidelines. The 5 primary sources used are listed in the Research Papers section above, each linked to its PubMed entry. See our editorial standards for how we research and review peptide profiles.
Last reviewed. by the Peptide Reference Editorial Team. Spot an error? Email a correction.
Not medical advice. Information on this page is for educational and research reference only. Many peptides covered are not approved for human use. See our full medical disclaimer.
Related Peptides
5-Amino-1MQ
A pill that aims to switch fat cells from 'storage mode' to 'burning mode' by blocking an enzyme (NNMT) that is overactive in the fat tissue of overweight people. Not technically a peptide, but commonly sold alongside them. Unlike appetite suppressants, this targets the fat cells directly rather than making you eat less. The science is promising in lab studies, but there are no completed human trials yet.
Adipotide
An extreme experimental approach to fat loss — it physically destroys the blood vessels that feed fat tissue, starving fat cells until they die. Originally developed using anti-cancer technology at MD Anderson Cancer Center. While it did reduce fat in monkey studies, it also caused serious kidney damage, which has effectively stopped its development. Not available for human use.
AICAR
A natural compound that activates your cells' energy sensor — the same pathway that turns on during exercise. Mimics the metabolic effects of endurance exercise at the cellular level, helping with fat burning, glucose uptake, and building more mitochondria. Banned by WADA as a metabolic modulator after detection in professional cycling.
Amycretin
Novo Nordisk's next-generation weight loss drug — the first single molecule that combines two appetite hormones (GLP-1 and amylin) in one shot. The same effect that CagriSema needs two drugs to achieve, amycretin does on its own. In Phase 1b/2a trials, people lost up to 22% of their body weight in 36 weeks, and a once-daily oral pill version is being developed alongside the weekly injection. Phase 3 trials began in 2026. Also known as zenagamtide.